AcuraStem Entered into a License Agreement with Takeda to Advance PIKFYVE Therapies for Amyotrophic Lateral Sclerosis
Shots:
- AcuraStem will receive an up front and additional fees of ~$580M upon achievement of milestones along with royalties on net sales of any commercial products. The companies collaborated to develop and commercialize AcuraStem's PIKFYVE targeted therapeutics incl. AS-202 for ALS
- Takeda to get an exclusive license globally to AcuraStem's PIKFYVE program & will lead other development activities incl. clinical development, regulatory affairs & global commercialization. AcuraStem will lead certain activities to advance AS-202 IND enabling studies and characterize potential backup ASOs
- ASO-mediated suppression of PIKFYVE can restore motor function, reduce neurodegeneration & improve survival in multiple in vivo models of ALS & FTD
Ref: PR Newswire | Image: Takeda
Related News:- Takeda and HUTCHMED Report EMA’s Validation of MAA for Fruquintinib to Treat Metastatic Colorectal Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
